Survinin expression in patients with breast cancer during chemotherapy

Marsicano, Sarah R; Kuniyoshi, Renata Kelly; Gehrke, Flávia S.; Alves, Beatriz da Costa Aguiar; Azzalis, Ligia Ajaime; Fonseca, Fernando L. A.

doi:10.1007/s13277-014-2979-5

Cited by 8 publications

(6 citation statements)

References 18 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, we found high expression of BIRC5 to be associated with worse clinical outcome in human breast cancer patients ( Supplementary Fig. 10c ), consistent with previous analyses of much smaller cohorts 28 29 . Lastly, knockdown of BIRC5-induced apoptosis and/or reduced colony formation capacity of breast cancer cell lines of the basal 30 , HER2 31 and luminal 32 subtypes, further supporting its subtype-independent oncogenic role in breast cancer.…”

Section: Resultssupporting

confidence: 90%

The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis

Ben‐David

Khadka

et al. 2016

Nat Commun

View full text Add to dashboard Cite

Aneuploidy and copy-number alterations (CNAs) are a hallmark of human cancer. Although genetically engineered mouse models (GEMMs) are commonly used to model human cancer, their chromosomal landscapes remain underexplored. Here we use gene expression profiles to infer CNAs in 3,108 samples from 45 mouse models, providing the first comprehensive catalogue of chromosomal aberrations in cancer GEMMs. Mining this resource, we find that most chromosomal aberrations accumulate late during breast tumorigenesis, and observe marked differences in CNA prevalence between mouse mammary tumours initiated with distinct drivers. Some aberrations are recurrent and unique to specific GEMMs, suggesting distinct driver-dependent routes to tumorigenesis. Synteny-based comparison of mouse and human tumours narrows critical regions in CNAs, thereby identifying candidate driver genes. We experimentally validate that loss of Stratifin (SFN) promotes HER2-induced tumorigenesis in human cells. These results demonstrate the power of GEMM CNA analysis to inform the pathogenesis of human cancer.

show abstract

Section: Resultssupporting

confidence: 90%

The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis

Ben‐David

Khadka

et al. 2016

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Overexpression of BIRC5 in breast cancer is associated with increased resistance to chemotherapy, radiotherapy, increased grade and tumour size, as well as with the decreased survival rate [47]. According to Marsicano et al breast cancer patients with higher expression of BIRC5 have signi cantly greater chance of developing metastasis than patients with lower expression [48]. Similar results were observed during present study which suggested that BIRC5 overexpression could be a potential prognostic and diagnostic biomarker in breast cancer.…”

Section: Discussionsupporting

confidence: 87%

Up-regulation of FN1, Activation of Maturation Promoting Factor and Associated Signaling Pathway Facilitates Epithelial-Mesenchymal Transition, Inhibits Apoptosis and Elevates Proliferation Rate of Breast Cancer Cells: In Silico Analysis of Microarray Datasets

Hameed

Ejaz

2020

Preprint

View full text Add to dashboard Cite

Background: Knowing that the molecular mechanisms underlying breast cancer (BC) are not yet fully understood it was considered worth to launch investigation for the detection of key molecular pathways and associated genes and proteins. Methods: In total two microarray based datasets (GSE10810 and GSE29431), consisting of 89 breast cancer samples and 31 controls, were retrieved from the Gene Expression Omnibus (GEO) database and processed to identify the differentially expressed genes (DEGs). The pathway and functional enrichment analyses of DEGs were performed using DAVID online tool. Protein-Protein interaction (PPI) network was constructed using an online tool STRING and visualized through Cytoscape software to identify the significant module and hub genes via MCODE and Cytohubba applications. The identified hub genes were then further analyzed to document their response in Kaplan-Meier (KM) survival curve analysis, investigate differential expression profile and its correlation with promoter’s methylation status, and finally for the construction of the gene-drug interaction network. Results: In total 449 DEGs were detected including 151 up-regulated and 298 down-regulated genes. The identified DEGs were enriched in various cancer related biological functions and pathways. Based on PPI network analysis of the DEGs, six hub genes, CDK1, FN1, AURKA, CCNB2, BIRC5, and TOP2A, were correlated with worse overall survival (OS) of the breast cancer patients. Conclusion: The extensive in silico analysis has been helpful to evaluate evidence highlighting the prominent role played by the identified hub genes in stimulating breast tumor growth through the activation of Maturation Promoting Factor (MPF), PI3K/AKT signaling, and associated pathways that could be targeted for devising effective treatment strategies.

show abstract

“…Thus, our findings provided evidence that BIRC5 could be a useful predictive prognostic marker for breast cancer. Indeed, several studies have reported BIRC5 as a prognostic marker in breast cancer through experimental evidences [25][26][27]. However, the sample size is small and the evidence is insufficient for a single experimental paper.…”

Section: Discussionmentioning

confidence: 99%

Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis

et al. 2020

View full text Add to dashboard Cite

Aims: Baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5) plays vital roles in carcinogenesis by influencing cell division and proliferation and by inhibiting apoptosis. However, the prognostic significance of BIRC5 remains unclear in breast cancer. Methods: BIRC5 expression and methylation status were evaluated using the Oncomine and The Cancer Genome Atlas (TCGA) databases. The relevance between BIRC5 and different clinicopathological features as well as survival information was analyzed using the bc-GenExMiner database and Kaplan-Meier Plotter. BIRC5-drug interaction network was obtained using the Comparative Toxicogenomics Database. Results: Based on the results from databases and own hospital data, BIRC5 was higher expressed in different breast cancer subtypes compared with the matched normal individuals. Hormone receptors were negatively correlated with BIRC5 expression, whereas the Scarff-Bloom-Richardson (SBR) grade, Nottingham Prognostic Index (NPI), human epidermal growth factor receptor-2 (HER-2) status, basal-like status, and triple-negative status were positively related to BIRC5 level in breast cancer samples with respect to normal tissues. High BIRC5 expression was responsible for shorter relapse-free survival, worse overall survival, reduced distant metastasis free survival, and increased risk of metastatic relapse event. BIRC5-drug interaction network indicated that several common drugs could modulate BIRC5 expression. Furthermore, a positive correlation between BIRC5 andcell-division cycle protein 20 (CDC20) gene was confirmed. Conclusion: BIRC5 may be adopted as a promising predictive marker and potential therapeutic target in breast cancer. Further large-scale studies are needed to more precisely confirm the value of BIRC5 in treatment of breast cancer.The Breast Cancer Gene-Expression Miner v4.1 (bc-GenExMiner v4.1, http://bcgenex.centregauducheau.fr/BC-GEM), an open access database of published annotated genomics data, was utilized to analyze the relevance between BIRC5 and specific clinicopathological features of breast cancer [16,17]. Association between BIRC5 and metastatic relapse event was assessed using the prognostic module, and correlation of BIRC5 and co-expressed cell-division cycle protein 20 (CDC20) was evaluated using the correlation module. UCSC XenaThe UCSC Xena browser (http://xena.ucsc.edu/) was used to analyze the TCGA Breast Cancer data using the level 3 data. The heatmap and correlation between BIRC5 and CDC20 were then constructed. Kaplan-Meier PlotterThe Kaplan-Meier Plotter (http://kmplot.com/analysis/), a web tool capable to check the effect of 54675 genes on survival using 5143 clinical breast cancer samples, was applied to show the prognostic value of BIRC5 in relapse-free survival, overall survival, and distant metastasis-free survival [18]. The hazard ratio (HR) with 95% confidence interval (CI), and log-rank P-value were calculated automatically.

show abstract

Survinin expression in patients with breast cancer during chemotherapy

Cited by 8 publications

References 18 publications

The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis

The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis

Up-regulation of FN1, Activation of Maturation Promoting Factor and Associated Signaling Pathway Facilitates Epithelial-Mesenchymal Transition, Inhibits Apoptosis and Elevates Proliferation Rate of Breast Cancer Cells: In Silico Analysis of Microarray Datasets

Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis

Contact Info

Product

Resources

About